VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature.

Unlike during development, blood vessels in the adult are generally thought not to require VEGF for normal function. However, VEGF is a survival factor for many tumor vessels, and there are clues that some normal blood vessels may also depend on VEGF. In this study, we sought to identify which, if any, vascular beds in adult mice depend on VEGF for survival. Mice were treated with a small-molecule VEGF receptor (VEGFR) tyrosine kinase inhibitor or soluble VEGFRs for 1-3 wk. Blood vessels were assessed using immunohistochemistry or scanning or transmission electron microscopy. In a study of 17 normal organs after VEGF inhibition, we found significant capillary regression in pancreatic islets, thyroid, adrenal cortex, pituitary, choroid plexus, small-intestinal villi, and epididymal adipose tissue. The amount of regression was dose dependent and varied from organ to organ, with a maximum of 68% in thyroid, but was less in normal organs than in tumors in RIP-Tag2-transgenic mice or in Lewis lung carcinoma. VEGF-dependent capillaries were fenestrated, expressed high levels of both VEGFR-2 and VEGFR-3, and had normal pericyte coverage. Surviving capillaries in affected organs had fewer fenestrations and less VEGFR expression. All mice appeared healthy, but distinct physiological changes, including more efficient blood glucose handling, accompanied some regimens of VEGF inhibition. Strikingly, most capillaries in the thyroid grew back within 2 wk after cessation of treatment for 1 wk. Our findings of VEGF dependency of normal fenestrated capillaries and rapid regrowth after regression demonstrate the plasticity of the adult microvasculature.

[1]  Ma Dong,et al.  Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .

[2]  A. Jubb,et al.  Plasmalemmal vesicle‐associated protein (PLVAP) is expressed by tumour endothelium and is upregulated by vascular endothelial growth factor‐A (VEGF) , 2005, The Journal of pathology.

[3]  R. Gaiser,et al.  Circulating Angiogenic Factors and the Risk of Preeclampsia , 2005 .

[4]  P. Carmeliet,et al.  Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. , 2004, Biochemical and biophysical research communications.

[5]  M. Ratner.  Genentech discloses safety concerns over Avastin , 2004, Nature Biotechnology.

[6]  R. Stan,et al.  PV1 is a key structural component for the formation of the stomatal and fenestral diaphragms. , 2004, Molecular biology of the cell.

[7]  Gavin Thurston,et al.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.

[8]  J. Folkman.  Endogenous angiogenesis inhibitors , 2004, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[9]  R. Herbst,et al.  Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[10]  Gavin Thurston,et al.  Age-Related Changes in Vascular Endothelial Growth Factor Dependency and Angiopoietin-1–Induced Plasticity of Adult Blood Vessels , 2004, Circulation research.

[11]  E. Foster,et al.  New technique for measurement of left ventricular pressure in conscious mice. , 2004, American journal of physiology. Heart and circulatory physiology.

[12]  G. Vrensen,et al.  In Vivo Angiogenic Phenotype of Endothelial Cells and Pericytes Induced by Vascular Endothelial Growth Factor-A , 2004, Journal of Histochemistry and Cytochemistry.

[13]  D. Hicklin,et al.  Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy , 1998, Cancer and Metastasis Reviews.

[14]  Wei Zhang,et al.  A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model , 2004, Angiogenesis.

[15]  D. McDonald,et al.  Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. , 2003, The American journal of pathology.

[16]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[17]  D. Melton,et al.  Role of VEGF-A in Vascularization of Pancreatic Islets , 2003, Current Biology.

[18]  Jianzhong Huang,et al.  Regression of established tumors and metastases by potent vascular endothelial growth factor blockade , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Mccarthy.  Antiangiogenesis drug promising for metastatic colorectal cancer , 2003, The Lancet.

[20]  G. Camussi,et al.  Altered angiogenesis and survival in human tumor‐derived endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  G. Frantz,et al.  Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. , 2003, Endocrinology.

[22]  A. Tsuchida,et al.  Antiobesity and antidiabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance , 2003, International Journal of Obesity.

[23]  R. Kalluri,et al.  Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria* , 2003, The Journal of Biological Chemistry.

[24]  J. Haigh,et al.  Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. , 2003, The Journal of clinical investigation.

[25]  T. Libermann,et al.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia , 2003 .

[26]  David S. Park,et al.  Glomerular endothelial fenestrae in vivo are not formed from caveolae. , 2002, Journal of the American Society of Nephrology : JASN.

[27]  G. Pacini,et al.  Insufficient islet compensation to insulin resistance vs. reduced glucose effectiveness in glucose-intolerant mice. , 2002, American journal of physiology. Endocrinology and metabolism.

[28]  G. Yancopoulos,et al.  VEGF-Trap: A VEGF blocker with potent antitumor effects , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Grunberger,et al.  Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. , 2002, Diabetes.

[30]  J. Hennig,et al.  PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. , 2002, Cancer research.

[31]  S. Wiegand,et al.  Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. , 2002, Endocrinology.

[32]  G. Vrensen,et al.  Expression of Vascular Endothelial Growth Factor Receptors 1, 2, and 3 in Quiescent Endothelia , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[33]  P. Carmeliet,et al.  Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.

[34]  K. Alitalo,et al.  Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. , 2002, The American journal of pathology.

[35]  D. Hanahan,et al.  VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. , 2002, Cancer cell.

[36]  K. Tomita,et al.  Glomerular endothelial cells are maintained by vascular endothelial growth factor in the adult kidney. , 2001, The Tohoku journal of experimental medicine.

[37]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[38]  W Grossman,et al.  LV systolic performance improves with development of hypertrophy after transverse aortic constriction in mice. , 2001, American journal of physiology. Heart and circulatory physiology.

[39]  C. Wahlestedt,et al.  Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. D'Amato,et al.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  P. Hirth,et al.  Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. , 2000, The Journal of clinical investigation.

[42]  K. Alitalo,et al.  VEGF‐C and VEGF‐D expression in neuroendocrine cells and their receptor, VEGFR‐3, in fenestrated blood vessels in human tissues , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  Cherrington,et al.  SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. , 2000, Cancer research.

[44]  K. Alitalo,et al.  Amniotic Fluid–Soluble Vascular Endothelial Growth Factor Receptor‐1 in Preeclampsia , 2000, Obstetrics and gynecology.

[45]  M. Wolfe,et al.  GIP biology and fat metabolism. , 1999, Life sciences.

[46]  J. Habener,et al.  The adipoinsular axis: effects of leptin on pancreatic β-cells , 2000 .

[47]  M. Clauss.  Molecular Biology of the VEGF and the VEGF Receptor Family , 2000, Seminars in thrombosis and hemostasis.

[48]  K. Alitalo,et al.  Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors , 1999, Cancer.

[49]  G. Palade,et al.  PV-1 is a component of the fenestral and stomatal diaphragms in fenestrated endothelia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  K. Alitalo,et al.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. , 1999, The American journal of pathology.

[51]  M Aguet,et al.  VEGF is required for growth and survival in neonatal mice. , 1999, Development.

[52]  S. Iseki,et al.  Immunohistochemical localization of vascular endothelial growth factor in the globule leukocyte/mucosal mast cell of the rat respiratory and digestive tracts , 1999, Histochemistry and Cell Biology.

[53]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[54]  B. Keyt,et al.  Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro * , 1998, The Journal of Biological Chemistry.

[55]  K.,et al.  Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[56]  H. Augustin,et al.  Antiangiogenic tumour therapy: will it work? , 1998, Trends in pharmacological sciences.

[57]  E. Keshet,et al.  A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. , 1998, Development.

[58]  Kenneth J. Hillan,et al.  Vascular endothelial growth factor is essential for corpus luteum angiogenesis , 1998, Nature Medicine.

[59]  S. Iseki,et al.  Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. , 1998, Archives of histology and cytology.

[60]  Vascular Endothelial Growth Factor Induces Endothelial Fenestrations In Vitro , 1998, The Journal of cell biology.

[61]  R K Jain,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[63]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[64]  J. Stone,et al.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.

[65]  G. Palade,et al.  Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. , 1995, Journal of cell science.

[66]  Georg Breier,et al.  Molecular Mechanisms of Developmental and Tumor Angiogenesis , 1994, Brain pathology.

[67]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[68]  A. Harris,et al.  Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. , 1992, Seminars in cancer biology.

[69]  J. Schmidley,et al.  Anionic sites on the luminal surface of fenestrated and continuous capillaries of the CNS , 1986, Brain Research.

[70]  D. Hanahan,et al.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.

[71]  M. Tavassoli,et al.  Transendothelial transport (transcytosis) of iron-transferrin complex in the bone marrow. , 1984, Journal of ultrastructure research.

[72]  Renkin Em.  Relation of capillary morphology to transport of fluid and large molecules: a review. , 1979 .

[73]  E. Renkin.  Relation of capillary morphology to transport of fluid and large molecules: a review. , 1979, Acta physiologica Scandinavica. Supplementum.

[74]  N. Simionescu,et al.  Structural aspects of the permeability of the microvascular endothelium. , 1979, Acta physiologica Scandinavica. Supplementum.